Singapore markets open in 1 hour 27 minutes
  • Straits Times Index

    3,000.37
    +26.50 (+0.89%)
     
  • S&P 500

    3,819.72
    -50.57 (-1.31%)
     
  • Dow

    31,270.09
    -121.43 (-0.39%)
     
  • Nasdaq

    12,997.75
    -361.04 (-2.70%)
     
  • BTC-USD

    50,904.48
    +3,106.23 (+6.50%)
     
  • CMC Crypto 200

    1,014.06
    +25.96 (+2.63%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Gold

    1,707.70
    -8.10 (-0.47%)
     
  • Crude Oil

    60.95
    -0.33 (-0.54%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • Nikkei

    29,559.10
    +150.93 (+0.51%)
     
  • Hang Seng

    29,880.42
    +784.56 (+2.70%)
     
  • FTSE Bursa Malaysia

    1,588.45
    +18.58 (+1.18%)
     
  • Jakarta Composite Index

    6,376.76
    +17.55 (+0.28%)
     
  • PSE Index

    6,942.76
    +23.22 (+0.34%)
     

Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

·2-min read

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2020 results after the financial markets close on Wednesday, February 24, 2021. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2020 financial and operating results.

Conference Call/Webcast Details:
Date:
February 24, 2021
Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)
Toll Free Dial-In Number: (855) 427-4396
International Dial-In Number: (484) 756-4261
Conference ID: 7178576
Webcast Link: https://edge.media-server.com/mmc/p/272ym8kz

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring, and optional automated insulin delivery technology. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslimX2 and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at www.linkedin.com/company/TandemDiabetes.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005833/en/

Contacts

Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com